Dupixent

Dupixent is a monoclonal antibody medication developed through a collaboration between Regeneron Pharmaceuticals and Sanofi. It is approved for the treatment of several chronic inflammatory conditions driven by type 2 inflammation, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The drug represents a significant advancement in biologic therapy for patients with these difficult-to-manage diseases, offering a targeted mechanism that differs from traditional immunosuppressants.

Medical uses

Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged six months and older who are candidates for systemic therapy. In asthma, it is approved for add-on maintenance treatment of moderate-to-severe disease characterized by an eosinophilic phenotype or with oral corticosteroid dependence. For chronic rhinosinusitis with nasal polyps, it is used as an add-on therapy in adults with inadequate response to intranasal corticosteroids. Additional approvals include treatment for eosinophilic esophagitis and prurigo nodularis, following reviews by the U.S. Food and Drug Administration and the European Medicines Agency.

Mechanism of action

Dupixent is a fully human monoclonal antibody that inhibits signaling of interleukin-4 and interleukin-13, two key cytokine proteins implicated in type 2 inflammation. It specifically binds to the shared alpha subunit of the interleukin-4 receptor, blocking the receptor complex utilized by both cytokines. This inhibition reduces downstream inflammatory responses, including the production of immunoglobulin E, the activation of inflammatory cells like eosinophils, and the release of pro-inflammatory chemokines. The mechanism was elucidated through research at the Regeneron Genetics Center, leveraging insights from human genetics.

Adverse effects

The most common adverse reactions include conjunctivitis, keratitis, oral herpes, and injection site reactions. Other notable effects may involve eosinophilia and arthralgia. Serious but less common risks include hypersensitivity reactions, such as angioedema and urticaria, and parasitic infections. Patients are monitored for the emergence of new ocular surface disease and are advised to receive age-appropriate immunizations prior to initiating therapy, as advised by the Centers for Disease Control and Prevention guidelines.

Clinical trials

The approval of Dupixent was supported by a robust clinical development program including the pivotal LIBERTY AD program for atopic dermatitis, the QUEST and VENTURE trials for asthma, and the SINUS-24 and SINUS-52 studies for nasal polyps. These randomized, double-blind, placebo-controlled trials demonstrated significant improvements in disease-specific scores, such as the Eczema Area and Severity Index, and reductions in exacerbation rates. Long-term extension studies, like the LIBERTY AD CHRONOS trial, have shown sustained efficacy and a consistent safety profile over several years of treatment.

Society and culture

Dupixent has had a substantial impact on the treatment landscape for allergic and inflammatory diseases, becoming a blockbuster therapy for Regeneron and Sanofi. Its development was recognized with the Prix Galien USA Award for Best Biotechnology Product. The drug's high cost has sparked discussions within healthcare systems like the National Health Service and among insurers regarding value-based pricing and patient access. Patient advocacy groups, including the Asthma and Allergy Foundation of America, have been instrumental in raising awareness and supporting individuals navigating treatment options. Category:Monoclonal antibodies Category:Immunomodulating drugs Category:Sanofi